Compare TMCI & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | ACIU |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 247.6M |
| IPO Year | 2021 | 2015 |
| Metric | TMCI | ACIU |
|---|---|---|
| Price | $4.25 | $2.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $5.50 | ★ $8.57 |
| AVG Volume (30 Days) | 188.0K | ★ 201.4K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | $422.39 |
| Revenue Next Year | $6.88 | $377.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.17 | $2.10 |
| 52 Week High | $6.92 | $4.00 |
| Indicator | TMCI | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 51.04 | 45.80 |
| Support Level | $3.82 | $2.40 |
| Resistance Level | $4.67 | $2.68 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 61.84 | 34.18 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The company operates and manages its business as a single segment: designing, manufacturing, and marketing medical devices for surgeons, ambulatory surgery centers, and hospitals related to the surgical management of bunion and related midfoot deformities.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.